These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25952267)

  • 1. Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.
    Kenanidis E; Potoupnis ME; Kakoulidis P; Leonidou A; Sakellariou GT; Sayegh FE; Tsiridis E
    Expert Opin Drug Saf; 2015 Jul; 14(7):1035-53. PubMed ID: 25952267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE; Baden M; Lems WF
    Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
    Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
    Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis].
    Tanana I; Oshima H
    Clin Calcium; 2006 Nov; 16(11):1851-7. PubMed ID: 17079852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
    Boling EP
    Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of glucocorticoid-induced osteoporosis.
    Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
    Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?
    Compston J
    Clin Endocrinol (Oxf); 2011 May; 74(5):547-50. PubMed ID: 21470278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal morbidity in inflammatory bowel disease.
    van Hogezand RA; Hamdy NA
    Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
    Gourlay M; Franceschini N; Sheyn Y
    Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for glucocorticoid-induced osteoporosis.
    Chiodini I; Merlotti D; Falchetti A; Gennari L
    Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
    Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
    J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis].
    Tanaka I; Oshima H
    Clin Calcium; 2007 Nov; 17(11):1738-44. PubMed ID: 17982195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
    Abadie EC; Devogealer JP; Ringe JD; Ethgen DJ; Bouvenot GM; Kreutz G; Laslop A; Orloff JJ; Vanderauwera PM; Delmas PD; Dere WH; Branco J; Altman RD; Avouac BP; Menkes CJ; Vanhaelst L; Mitlak BH; Tsouderos Y; Reginster JY
    Semin Arthritis Rheum; 2005 Aug; 35(1):1-4. PubMed ID: 16084217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.